



(51) International Patent Classification:

C07D 498/04 (2006.01) **A61P 9/14** (2006.01)
C07D 519/00 (2006.01) **A61P 11/00** (2006.01)
A61K 31/519 (2006.01) **A61P 13/12** (2006.01)
A61P 3/10 (2006.01) **A61P 25/28** (2006.01)
A61P 7/02 (2006.01) **A61P 29/00** (2006.01)
A61P 9/04 (2006.01) **A61P 31/02** (2006.01)
A61P 9/10 (2006.01) **A61P 35/00** (2006.01)
A61P 9/12 (2006.01)

(21) International Application Number:

PCT/EP2009/004770

(22) International Filing Date:

2 July 2009 (02.07.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08290694.2 15 July 2008 (15.07.2008) EP

(71) Applicant (for all designated States except US):
SANOFI-AVENTIS [FR/FR]; 174 Avenue de France,
F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KADEREIT, Dieter** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHAEFER, Matthias** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **CZECHTIZKY, Werngard**

[AT/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: **KUJATH, Eckard**; Sanofi-aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Gebäude K 801, 65926 Frankfurt am Main (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS



(57) **Abstract:** The present invention relates to oxazolo-pyrimidine compounds of the formula I in which A, R¹, R² and R³ are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.